The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
Abbott's PCR instrument will help the biopharma companies identify isocitrate dehydrogenase mutations in patients with acute myeloid leukemia.